Acerta Pharma BV

🇳🇱Netherlands

Country: 🇳🇱Netherlands

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.acerta-pharma.com

Clinical Trials

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Phase 1

Active, not recruiting

Conditions: Glioblastoma Multiforme

Interventions: Drug: ACP-196

First Posted Date: 2015-10-27

Last Posted Date: 2024-12-06

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 24

Registration Number: NCT02586857

Locations: 🇺🇸
Research Site, Vancouver, Washington, United States

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

Phase 2

Terminated

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: ACP-196
Drug: Nab-paclitaxel
Drug: Gemcitabine

First Posted Date: 2015-10-07

Last Posted Date: 2019-08-28

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 3

Registration Number: NCT02570711

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Ventura Clinical Trials, Ventura, California, United States

and more 6 locations

Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: acalabrutinib and pembrolizumab combination
Drug: Acalabrutinib

First Posted Date: 2015-09-01

Last Posted Date: 2019-09-25

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 78

Registration Number: NCT02537444

Locations: 🇺🇸
Arizona Gynecology Oncology, Tucson, Arizona, United States
🇺🇸
Jordan Center For Gynecologic Cancer At Penn, Philadelphia, Pennsylvania, United States

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Acalabrutinib
Drug: Ibrutinib

First Posted Date: 2015-06-23

Last Posted Date: 2024-11-01

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 533

Registration Number: NCT02477696

Locations: 🇬🇧
Research Site, Surrey, United Kingdom

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Obinutuzumab
Drug: Acalabrutinib
Drug: Chlorambucil

First Posted Date: 2015-06-19

Last Posted Date: 2024-12-19

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 535

Registration Number: NCT02475681

Locations: 🇬🇧
Research Site, Wolverhampton, United Kingdom

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: pembrolizumab
Drug: Acalabrutinib

First Posted Date: 2015-05-27

Last Posted Date: 2019-09-12

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 78

Registration Number: NCT02454179

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Pembrolizumab
Drug: Acalabrutinib

First Posted Date: 2015-05-19

Last Posted Date: 2019-09-12

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 74

Registration Number: NCT02448303

Locations: 🇺🇸
Western Regional Medical Center/Cancer Treatment Center of America, Goodyear, Arizona, United States

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: acalabrutinib

First Posted Date: 2015-03-13

Last Posted Date: 2019-04-02

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 31

Registration Number: NCT02387762

Locations: 🇺🇸
San Marcus Research Clinic, Inc., Hialeah, Florida, United States
🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States

and more 14 locations

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: ACP-196
Drug: ACP-196 in combination with pembrolizumab

First Posted Date: 2015-02-12

Last Posted Date: 2019-10-01

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 77

Registration Number: NCT02362048

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Phase 1

Active, not recruiting

Conditions: CLL
Small Lymphocytic Lymphoma (SLL)
Burkitt Lymphoma
Mediastinal Large B Cell Lymphoma
Richter's Syndrome
Waldenström Macroglobulinemia
Follicular Lymphoma (FL)
Indolent Non Hodgkin Lymphoma
Multiple Myeloma
Marginal Zone Lymphomas

Interventions: Drug: Acalabrutinib
Drug: Pembrolizumab

First Posted Date: 2015-02-12

Last Posted Date: 2024-11-20

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 161

Registration Number: NCT02362035

Locations: 🇺🇸
Research Site, Yakima, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy